Asia-Pacific Diagnostic Tests Market Is Predicted to Grow Around USD 351.8 Billion By 2030

The Asia-Pacific diagnostic tests market size was worth around USD 160.6 Billion in 2022 and is predicted to grow to around USD 351.8 Billion by 2030 with a compound annual growth rate (CAGR) of roughly 10.31% between 2023 and 2030.

The Asia-Pacific diagnostic tests industry refers to the research, designing, production, and distribution of diagnostic tools that are used for several medical purposes. However, the market only deals with issues in the Asia-Pacific region and focuses majorly on countries such as China, Japan, India, Australia, South Korea, and others. Diagnostic tests are medicinal tools that are used for accurate diagnosis of several medical conditions, diseases, or infections in patients. It includes a wide range of equipment with some devices being more general in terms of diagnosis while some tools are produced for specific conditions.

The regional market plays a crucial role in the global industry due to the ongoing rise in investment directed toward more research along with a higher potential for further expansion in Asian countries. During the forecast period, the industry may witness high growth but will also face certain restrictions and challenges.

The Asia-Pacific diagnostic tests market is projected to grow owing to the increasing geriatric population in the regions of Japan, China, and other countries. The elderly population is more vulnerable to contracting several conditions some of which are age-induced and some may be due to previous medical conditions. As per official reports, more than 28% of Japan’s population is over 65 years of age which directly impacts the country’s healthcare system.

In addition to this, the increasing investment toward developing new and accurate diagnostic tools, especially in the oncology segment could lead to higher growth revenue. For instance, in 2020, India spent nearly INR 2300 crore on the treatment of oral cancer in the region. In addition to this, the regions of Japan, India, South Korea, and China are investing in drastic technological improvements and focusing on breakthrough diagnostic tests such as molecular diagnostic and point-of-care testing. The increasing prevalence of medical diseases such as cancer and diabetes is another leading cause of the regional market size.

However, the Asia-Pacific diagnostic test industry also deals with several restraints in terms of lack of awareness and education. A large part of the population, especially in underdeveloped countries, does not have the necessary awareness about the different types of diagnostic tools for specific medical conditions. This part of the patient group solely relies on government drives or initiatives by healthcare agencies. The frequency of such programs may be less as compared to the population strength. Furthermore, the increasing regulatory hurdles against approval and commercial sale of diagnostic tests are another significant barrier that greatly restricts market growth.

The growing efforts toward self-dependence could provide growth opportunities, while the large market fragmentation could challenge market growth.

The Asia-Pacific diagnostic tests market is segmented based on technology, approach, application, end-user, and region.

Based on technology, the regional market segments are next-generation sequencing, immunoassay-based substrate technology, spectroscopy-based, microfluidics, and others.

Based on approach, the Asia-Pacific diagnostic tests market segments are in-vitro diagnostic instrument, molecular diagnostic instrument, and point of care testing instrument. In 2022, the industry witnessed the highest growth in the in-vitro diagnostic instrument segment. This approach includes performing diagnostic tests using samples of urine, blood, or other bodily fluids outside of the body. The tests are performed for a variety of medical conditions, ranging from mild to serious such as infectious diseases, cancer, and genetic disorders.

In-vitro tests are conducted across several healthcare settings, including hospitals and dedicated diagnostic centers. Another significant contributor in this segment is molecular diagnostic instruments that are used for diagnosing infectious diseases and genetic disorders. In 2020, India reported more than 1.39 million new cases per country’s healthcare agency.

Based on application, the regional market is divided into gynecology, cardiology, orthopedics, oncology, odontology, gastroenterology, neurology, and others.

Based on end-user, the Asia-Pacific diagnostic tests market divisions are specialty clinics, hospitals & diagnostic center, blood banks, homecare, research institute, ambulatory surgical centers, and others. The hospitals & diagnostic center segment is expected to witness the highest growth during the forecast period. These facilities provide excellent healthcare services and access to several diagnostic tools under one roof. They are also, generally, the first point of contact for the patients. Specialty clinics often tend to the needs of patients with specific conditions since they specialize in the treatment of these issues and the segment may generate high growth in the coming years. As per WHO, India spent nearly 3.6% of its gross domestic product (GDP) on healthcare in 2020.

The Asia-Pacific diagnostic tests market is expected to witness the highest growth in Japan mainly due to the protective care approach adopted by the regional government to ensure 100% accessibility to quality medical care for its residents. China is expected to emerge as one of the highest contributing nations in the regional market due to the growing emphasis on developing the country’s medical infrastructure.

Some of the largest medical diagnostic tool manufacturers are present in China that have currently amplified their spending on further research & development. India is witnessing a surge in healthcare expenditure from the government’s side as demand for medical diagnosis and care has increased over the years. The country is focusing on the domestic production of diagnostic tests for several conditions including cancer and other serious issues.

This review is based on a report by Zion Market Research, titled “Asia-Pacific Diagnostic Tests Market By Technology (Next-Generation Sequencing, Immunoassay-Based, Substrate Technology, Spectroscopy-Based, Microfluidics, and Others), By Approach (In-Vitro Diagnostic Instrument, Molecular Diagnostic Instrument, and Point of Care Testing Instrument), By Application (Gynecology, Cardiology, Orthopedics, Oncology, Odontology, Gastroenterology, Neurology, and Others), By End-User (Specialty Clinics, Hospitals & Diagnostic Center, Blood Banks, Homecare, Research Institute, Ambulatory Surgical Centers, and Others), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2023 – 2030.”- Report at https://www.zionmarketresearch.com/report/asia-pacific-diagnostic-tests-market

Recent Developments:

• In June 2022, Mylab Discovery Solutions, an Indian healthcare company, announced the last of PregaScreen which is an at-home pregnancy test kit
• In January 2023, Atomo Diagnostic, an Australia-based healthcare company, signed a partnership with NG Biotech SAS for the production and sale of its pregnancy tests in global regions of Canada, the US, and New Zealand

The Asia-Pacific diagnostic tests market is led by players like:

• Mindray Medical International Limited
• Roche Diagnostics
• Bio-Rad Laboratories
• Abbott Laboratories
• Becton
• Dickinson and Company
• Siemens Healthineers
• F. Hoffmann-La Roche Ltd.
• Danaher Corporation
• QIAGEN N.V.
• Thermo Fisher Scientific
• Beckman Coulter Inc.
• Sysmex Corporation
• Bio-Rad Laboratories
• Hologic Inc.
• Ortho Clinical Diagnostics
• Cepheid Inc.
• Luminex Corporation
• Meridian Bioscience Inc.
• Eiken Chemical Co. Ltd.
• Nihon Kohden Corporation
• Alere Inc.
• BioMérieux SA
• DiaSorin S.p.A.
• Fujirebio Inc.
• Grifols S.A.

The global Asia-Pacific diagnostic tests market is segmented as follows:

By Technology

• Next-Generation Sequencing
• Immunoassay-Based
• Substrate Technology
• Spectroscopy-Based
• Microfluidics
• Others

By Approach

• In-Vitro Diagnostic Instrument
• Molecular Diagnostic Instrument
• Point of Care Testing Instrument

By Application

• Gynecology
• Cardiology
• Orthopedics
• Oncology
• Odontology
• Gastroenterology
• Neurology
• Others

By End-User

• Specialty Clinics
• Hospitals & Diagnostic Centers
• Blood Banks
• Homecare
• Research Institute
• Ambulatory Surgical Centers
• Others

By Region

• Asia Pacific
  • China
  • Japan
  • India
  • New Zealand
  • Australia
  • South Korea
  • Southeast Asia
• Indonesia
• Thailand
• Malaysia
• Singapore
• Rest of Southeast Asia
  • Rest of Southeast Asia

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com